Contract Services

Takeda selects leon’s MJR nano-technology for feasibility assessment

leon-nanodrugs is pleased to announce that its proprietary MicroJet Reactor (MJR) nano-technology has been selected by Takeda Pharmaceutical Company for a feasibility assessment that could potentially lead to the development of an innovative formulation of one of their current pipeline products.
leon-nanodrugs announced that the company has started a feasibility assessment collaboration with Takeda. Under this collaboration, leon will support Takeda`s formulation efforts to optimize solubility, bioavailability and stability for one of Takeda’s current pipeline products for drug delivery using leon’s proprietary nanotechnology platform –MicroJet Reactor (MJR).
leon`s platform can be used from early compound screening to production of market batches. Positive results from this feasibility study could potentially result in a long-term collaboration between the companies, and additional compounds may also be considered.
It is estimated that over 60% of pharmaceutical API’s are poorly soluble in water.  leon’s MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous precipitation process approach of the MJR technology is cost effective and easily scalable.
Dr Michael Mehler, CEO of leon-nanodrugs comments: “We are very pleased and proud that Takeda selected our MJR technology for a feasibility assessment with one of their compounds in development. It is a major milestone for our company to win Takeda, a globally leading pharmaceutical company, as a partner and we look forward to this collaboration with the goal to contributing to bring valuable new medicines to patients worldwide.”